FEIBA and Use of Blood Products in Cardiac Surgery
Status:
Completed
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to evaluate the feasibility of the prophylactic
administration of Factor VIII Inhibitor Bypass Activity (FEIBA) at termination of
cardiopulmonary bypass (CPB) period. Specifically, the proposed study is designed to
demonstrate the potential role of FEIBA administration in reducing the need for allogeneic
transfusion to treat refractory coagulopathy in high risk patients.
Phase:
Phase 1
Details
Lead Sponsor:
Oregon Health and Science University
Treatments:
Anti-inhibitor coagulant complex Coagulants Factor VIII